CMS Updates Medicare Coverage For LVADs, Artificial Hearts
Agency to eliminate “coverage with evidence development” status
Patient selection criteria will be the key to allowing CMS coverage of left ventricular assist devices (LVADs) when there is no longer a coverage with evidence development requirement, the US agency wrote.
You may also be interested in...
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the third of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including the final results of the MOMENTUM 3 trial of Abbott’s HeartMate 3 left-ventricular assist device and six-month results from the RADIANCE-HTN SOLO trial of ReCor’s Paradise renal denervation system, and more. Check out Part I and Part II of our ACC Results Recap.
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.